Categories
Digital Health MedTech Pharma Marketing

Internet of Things in Healthcare and Pharma

Internet of Things becomes one of the most impactful trends in Healthcare and Pharma industry. According to the Big Data in Internet of Things (IoT): Key Trends, Opportunities and Market Forecasts 2015 – 2020 report by Mind Commerce Publishing, value of Internet of Things in Healthcare will reach $117 billion by 2020. With CAGR of 15.1%, Healthcare will be the fastest growing segment in the whole IoT market.
See also: IoT in Financial Services and Banking
 

SeaaDr. Juan Manuel Romero, a cardiologist in Sonora, Mexico, engages in a pre-op consultation with Alma Guadalupe Xoletxilva. Wikimedia Commons.

Internet of Things: Definition

Internet of Things (IoT), sometimes called also Internet of Everything, is a concept of enabling Internet-based connection between computing devices embedded into everyday objects. Internet of Things is already technically feasible and applied in multiple scenarios. With wider adoption, Internet of Things brings revolutionary changes to existing processes in most, if not all industries..

Video: Healthcare – The Internet of Things and Big Data
https://www.youtube.com/watch?v=qO9unY31820
Video: Internet of Everything | True Stories of the Connected: Rural Healthcare in Northern Canada

Internet of Things in Healthcare and Pharma

Internet of Things applications are impacting all three stages of health care: prevention, diagnosis and treatment.
Wearable sensors and quantified self software embedded in smart-watches are good example of using Internet of Things in Healthcare for disease prevention and healthy lifestyle promotion. Going forward, wearable or digestible connected sensors are part of diagnosis useful especially in remote areas and in chronic conditions.
As for the treatment itself, connected packages and medication dispensers such as CleverCap, MedMinder or Philips Lifeline are used to improve patients adherence to the treatment. A step forward from adding connectivity to packages is putting it directly on medication. Proteus Digital Health, a company backed by Novartis and Oracle has already received FDA market clearance in the United States and a CE mark in Europe for its wearable and Ingestible Sensor devices.
https://www.youtube.com/watch?v=-hhOtjdkU34
Video: Proteus Digital Health – Your Health, Powered By You

Internet of Things in Clinical Environment: MBANs

MBAN stands for Medical Body Area Network and is a concept of low power network of body sensors worn directly or in close proximity to the patient. MBAN is connecting to the hub via LAN of health care facility (ie. hospital). MBAN allows constant monitoring of patient’s health parameters while in the facility, even while moving. Outside of the facility, MBAN may also serve patient – for example by connecting blood sugar level sensor with insulin injection pump.
https://www.youtube.com/watch?v=vloCv3J-Wo8

Video: Medical Body Area Networks (MBANS) should expand patient monitoring

Internet of Things and Big Data

With wider adoption of connected wearable sensors and MBANs the amount of available relevant real world evidence becomes so huge, that medical research may, at least partially, shift its paradigm from experimental to statistical approach. Instead of setting up costly trials and recruiting patients with specific conditions, investigators will be able to perform analysis of existing data gathered from already diagnosed and treated population.

Video: Data analytics: Changing the practice of medicine

Categories
Digital Health MedTech Pharma Marketing

Wearables in healthcare to be promoted by NHS England. What’s next?

NHS England has announced its plans to provide free WiFi in hospitals to push for adoption of wearable technology. It hopes that wearables can be used in clinical settings. At K-message we looked at wearable technology and quantified self impact on pharma in early 2014. Although NHS’s announcement brings wearables in healthcare one step closer, there is still a lot to do.

According to the research quoted by NHS over a fifth of patients with diabetes will have experienced a largely avoidable hypoglycemic episode whilst in hospital. Wearable technology may help doctors to detect deterioration early and act without delay. NHS England hopes, that connected sensors will be used to monitor health of people with long term conditions such as diabetes, heart failure, liver disease or asthma. The information gathered by wearable technology will be uploaded directly into patients’ records through the digital health services platform.
Nowadays, NHS maintains highly successful application (50 million hits per month) NHS Choices, that allows UK citizens to search and register for GP visit, book prescription and register for other services. NHS Choices provides also preliminary symptom checker, medical knowledge database and health related news promoting healthier lifestyle.
From the pharmaceutical marketing perspective embracing wearables in healthcare clear opportunity. Wearable (but also ingestible and implantable) devices and sensors will provide us with valuable real world evidence.With the mass adoption of such sensors assessment of treatment efficiency and drug safety will improve on unimaginable scale.  Use of wearables in healthcare may also greatly impact treatment adherence (making patient to take medication as and when prescribed). In general, it moves medicine from population-based to individual data based, truly personalized healthcare.

The types of physiological data points and the wearable sensors under development or on the market to monitor them. – Nature.com



Technology providers seeing vast business opportunity are joining those efforts. Then, they go back seeing how hard it is to operate in strictly regulated market.We all may remember how Google’s Larry Page and Sergey Brin were discussing their work on sensor contact lenses for diabetes (with Novartis/Alcon) and longevity medicine project of Calico. Their learning was in Sergey Brin’s words:

“Generally, health is just so heavily regulated. It’s just a painful business to be in. It’s just not necessarily how I want to spend my time. Even though we do have some health projects, and we’ll be doing that to a certain extent. But I think the regulatory burden in the U.S. is so high that think it would dissuade a lot of entrepreneurs.”

 
For pharmaceutical companies and healthcare providers this regulatory burden is given for their core business. For them, raise of wearable devices and mobile health applications raises some issues. Our smartphones, fitbits, jawbones and misfit shine wearables are not meant to be medical devices. Data acquired by wearables may not be accurate as they do not hae to be. They are not designed to the clinical and healthcare standard – there are no backup systems if the battery goes down, if user switches the phone in silent mode etc. Today wearable technology for pharma is still not good enough to bet patients safety on it. FDA’s guidance allows wearables in healthcare only as general wellness, low risk devices.
 
The solution may come from the alliance of pharma and technology. Novartis with Google and Qualcomm, UCB with MC10, GSK with Medidata have chosen this direction. Another may be innovative startups companies willing to align with regulatory and compliance burden for a benefit of entering profitable niche leftover by more established players.
K-message believes that finally wearables and more generally, the internet of things will change and shape the future of healthcare and pharmaceutical industry. If you know or, even better, make a product or service intended to be a part of this future we will be happy to cover your story.

Categories
Pharma Marketing

Traditional interaction with HCPs beats digital in impact on prescriptions?

Digital marketing loses against traditional interaction with HCPs says Cegedim Strategic Data (CSD). According to the study called Global Promotions Audit, traditional interactions are still much more common and more efficient in impact on prescription behavior.
To be honest, such a result is completely against what we preach at K-message. Digital tactics are supposed to reach wider audience, and properly executed can change behavior efficiently. What is more, we know that efficiency of digital can be measured.
CSD’s study, at the first sight, says otherwise. Why is that?
CSD collects data from physicians in Top 5 EU, USA, Japan, Brazil, Russia, China, Belgium, Canada and Poland. The research is part of syndicated panel, and respondents are physicians from primary and secondary care disciplines.
Obviously, digital maturity of surveyed markets differs, and CSD provides results by country. Even in the most advanced Japan, only 34% of contacts is classified as digital. For USA it is 24%, Poland 20%. Other countries have much lower proportion of digital interaction – Germany 5%, Brazil, Italy and Russia 2%, China just 1%.

Digital contacts by country Cegedim Strategic Data

This has to skew results. We do not know the size of the sample of German or Chinese HCPs, but even if it is 100 doctors per country, we cannot say anything relevant about impact of any factor that affected only few respondents in the group.
From CSD data, we can see that in 11 of 13 markets, a predominant channel of digital interaction with HCPs is emailing. This again puts digital in unfavorable light. Does an e-mail from sales rep counts as an interaction with HCP? Can we reasonably expect that e-mail alone will change HCPs decision for prescriptions? We should not, and this brings another surprise.
The most positive impact of digital interaction on prescription is declared in Canada where 55.6% of digital interactions led to positive intention to start or increase prescribing promoted brand. The most skeptical towards the digital were doctors from France, still 17.1% of those declared positive impacts.
CSD says that in every country impact of traditional interaction with HCPs was higher than for digital. But what are we comparing here? It is an email campaign versus face to face and telephone detailing, on-site meeting or event, delivery of printed materials.
Those results mean that HCPs should receive a proper, multi-channel campaign that combines e-mail (automated with marketing automation tools), remote detailing, on-site events supported with webcasts, websites that allow rich interaction and include order form for additional materials in print or in automated detailing.
CSD’s story is that their result shows a need for more of traditional approach. This is simply impossible due to market environment. But it would not be smart either. What we read from the data is that emailing alone can bring 20 to 50% impact on prescription, so pharmaceutical marketing job is to invest more in multichannel approach.

Categories
Pharma Marketing

Is Twitter for Pharma Banned by the FDA?

The recent FDA’s Office of Prescription Drug Promotion (OPDP) draft guidance on Internet/Social Media Platforms with Character Space Limitations – Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices effectively bans Twitter for pharma advertising. It does the same with Google Sitelink ads.
[box type=”info” align=”aligncenter” ]
K-messsage’s take on the FDA’s social media guidance from June 17th:
[checklist]
1. DO NOT use Twitter for promotional messaging about prescription drugs and medical devices
2. DO NOT use Google Sitelinks for promotional messaging about prescription drugs and medical devices
3. DO PERFORM social media monitoring to identify and engage in conversation about your prescription drugs and medical devices with misleading information on prescription drugs or medical devices
4. KEEP your Twitter presence for corporate and employer branding and for correcting misinformation
[/checklist]
[/box]
K-message believes that this is not what the Agency wanted to achieve, but we strongly suggest to all risk-averse pharmaceutical companies to cease any promotional activities for prescribed drugs in both space limited channels.
While the guidance includes imaginary examples of legally approved tweets and ads, in the real world it will not be possible to recreate such compliance for any of the existing products. Or at least it would cause a serious “Headhurtz” for the pharma marketing teams.

Headhurtz example Draft Guidance for Industry- Internet-Social Media Platforms with Character Space Limitations

 
FDA requires to include in the tweet both benefit and risk information, and to link from the tweet to full page with Important Safety Information, preferably using word “risk” in an URL. As tweet has only 140 characters, it would be almost impossible to crunch in risks related to the product, even if you decide to skip benefit part.
 
Nofocus tweet example Draft Guidance for Industry- Internet-Social Media Platforms with Character Space Limitations

 
The same happens with FDA’s proposal on how to use Google Sitelink ad format. The Agency may not know that, but what is displayed in the ad depends on the Google’s own algorithm, that tries to increase CTR. The chance of having very similar, risk focused links displayed under the ad, even if we manage to be always on the top of SERP, is limited. From our perspective the risk of not being able to follow the guidance is too high. Our recommendation is to use other Search Engine Marketing tactics instead.
 
Above does not mean, that pharma marketing on twitter is no longer possible. From the global perspective, the new regulation (if adopted without changes), affects only the United States market. Globally, there is no promotional activity directed to consumers, so there is no need to send promotional tweets. Instead, pharmaceutical firms focus on their corporate brands and disease awareness education – without promoting or even mentioning prescription drugs in the communication. So, yes, advertising prescription drugs  and medical devices on twitter seems to be forbidden. But you should keep your presence there for
 
On the brighter side of the regulatory proposals, another draft guidance has been published. The Internet/Social Media Platforms: Correcting Independent Third-party Misinformation About Prescription Drugs and Medical Devices document paves the way to correct misleading or false information on pharmaceutical products and medical devices that is spreading over the web.
It will hopefully encourage pharma marketing departments worldwide to take a closer look into the social media and web monitoring in a search for online conversations around pharmaceutical brands and products. As the recent Accenture’s study shows, patients are expecting more of such engagement from the industry.
 

Categories
Pharma Marketing

Cannes Lions Health 2014: is pharma advertising so bad?

Cannes Lions Health 2014 festival was supposed to be the world’s first contest of creativity in healthcare and pharma advertising. Made by advertising agencies and for advertising agencies, Lions Health could not find a grand prix winner in Cannes this year. Does it prove lack of creativity, or rather that the whole concept of advertising in the healthcare industry is wrong?
No grand prix of Cannes Lions Health 2014 was awarded. A Jury made only from the advertising agencies, focus on vague “creativity” and not measurable effects or validity of choice. From K-message perspective it is all failed, with the only exception of a Grand Prix for Good award given to Colombian League Against Cancer for its Cancer Tweets campaign.
[box type=”success” ]

Cancer Tweets

https://www.youtube.com/watch?v=pXWgL4NrJqg

Brand: LEAGUE AGAINST CANCER – BOGOTA
Agency: LEO BURNETT COLOMBIANA, COLOMBIA
Target: Disease Awareness Social Media Campaign
Credits:

Name Company Position
Fernando Hernandez Leo Burnett Colombiana General Creative Director
Mauricio Sarmiento Leo Burnett Colombiana General Creative Director
Carlos Oviedo Leo Burnett Colombiana Creative Director
Alexis Ospina Leo Burnett Colombiana Creative Director
Rafael Reina Leo Burnett Colombiana Creative Director
Andres Salamanca Leo Burnett Colombiana Copywriter
Alexis Ospina Leo Burnett Colombiana Copywriter
Andres Lopez Leo Burnett Colombiana Art Director
Rafael Reina Leo Burnett Colombiana Art Director
Julian Velez Leo Burnett Colombiana Art Director
Alejandra Melo Leo Burnett Colombiana Community Manager
Camilo Mendivelso Leo Burnett Colombiana Community Manager
Camilo Torres Leo Burnett Colombiana Community Manager
Cesar Peralta Leo Burnett Colombiana Community Manager
Carlos Leguizamon Leo Burnett Colombiana Community Manager
Carlos Oviedo Leo Burnett Colombiana Community Manager
Andres Salamanca Leo Burnett Colombiana Community Manager
Maicol Vera Leo Burnett Colombiana Web Designer
Natalia Valencia Leo Burnett Colombiana Account Director

Campaign Description:

A cancer that follows you virtually. Cancer is a silent disease, every year millions of people die for ignoring their symptoms. That’s why we created Cancertweets, an act that make people feel what it is like to have cancer and how easy is to ignore it. We created 7 Twitter accounts that represented 7 types of cancer and ‘spread out’ the virtual cancer throughout thousands of accounts. Virtual cancer acted as a real cancer: at first, followed silently. Then, started to manifest subtle; finally expressed its symptoms directly. Those who detected on time, virtual cancer stopped following them. Those who ignored it, received a final message.

[/box]
 
Unfortunately other campaigns did not bring anything innovative, striking or at least, very efficient in terms of communication, as you can see for yourself clicking at the entries list. At K-message we were not even disappointed, as this whole concept seems bit weird to us. Take a look at the President of the Jury explaining why no GrandPrix was awarded:

From our perspective it is not about “setting the bar” too high. Pharma marketing is just different. We talk about serious issues, we should base our communication on scientifically proven statements. The idea of “promoting” a pharmaceutical product to patients is from the very beginning dangerous and thus forbidden in most of the world. For the healthcare professionals, we should bear in mind that any additional noise may adversely impact their decisions and, in effect, patients well-being. Human brain while making decision can process 5 to 6 factors. In medicine there are usually hundreds of factors to be taken into account. Do we really need to produce more of it? Or shall we rather focus on making the process easier to congest, by making tools for better processing the scientific information about our products and diseases to be treated? .
Saying that, feel free to take a look at the Cannes Lions Health 2014  Gold Lions awarded campaigns. While they are not worth a Grand Prix, they are well executed. Our pick from those three would be Mind Your Meds. It puts digital tactics at the core, provides not only emotional message but also valuable information.
[box type=”success” ]

Cate Jackson


Brand: Simponi – Janssen
Agency: MCCANN HEALTH AUSTRALIA
Target: Promotional Communication to the Healthcare Professional: New Product Launch
Credits:
Name Company Position
June Laffey Mccann Health Executive Creative Director
Thomas Dirnberger Mccann Health Art Director
Kate Chisnall Mccann Health Art Director
Bob Johnson Mccann Health Art Director
Sophy Myer Mccann Health Account Director
Dick Sweeney Louis/Co Photographer
Glenn Edwards Castirian Editor
Tristan Coelho Composer/Produce

Campaign Description:

When you treat RA with Simponi, it only takes about ten minutes, once a month. This means Simponi is the treatment you hardly even notice. Great news when often RA is burden enough to a patient. We wanted to capture the non-invasive nature of Simponi in our creative. So we set out to capture a month of a Simponi patient on film and show how non-invasive it is. Literally. This film features a typical RA person – female between 50 and 60. It shows hundreds of moments (selected from over 10,000 shots captured by our photographer) that represent a month in the life of a Simponi patient, Cate Jackson. Amongst the hundreds of shots, there is only one that features Cate injecting herself with Simponi. The shots are run together so quickly in the film, it is near impossible to spot the moment that treatment takes place. This technique/idea highlights the fact that Simponi is very non-invasive, so you’ll hardly notice. After watching a collage of her life, a super tells us in the many shots/moments we just watched only one featured Simponi. The super then challenges: “Bet you hardly even noticed. Neither did Cate Jackson.”

[/box]
 
[box type=”success” ]

True Cost

[tabs type=”horizontal”][tabs_head][tab_title]Shampoo[/tab_title][tab_title]Tea[/tab_title][tab_title]Toothbrush[/tab_title][/tabs_head][tab]Bayer, Sativex: “True Cost” Campaign “Shampoo”

True Cost – Shampoo – Sativex

[/tab][tab]Bayer, Sativex: “True Cost” Campaign “Tea”
True Cost – Tea – Sativex

[/tab][tab]Bayer, Sativex: “True Cost” Campaign “Toothbrush”
True Cost – Toothbrush – Sativex

[/tab][/tabs]
Brand: Sativex – Bayer
Agency: LANGLAND Windsor, UNITED KINGDOM
Target: Promotional Communication to the Healthcare Professional: Brand Re-appraisal campaign
Credits:

Name Company Position
Andrew Spurgeon Langland Executive Creative Director
Andrew Morley Langland Art Director
Harry Yeates Langland Copywriter
Andrew Morley Langland Designer/Digital Designer
Whitney Andrews Langland Senior Account Director
Elizabeth Chambers Langland Group Account Director
Graham Robinson Langland Account Manager
Claire Martin Langland Art Buyer
Jessica Stonell Langland Art Worker

Campaign Description:

Spasticity is a symptom that develops late in the course of multiple sclerosis (MS), causing muscle spasm, weakness and stiffness. Patients lose their independence and are forced to rely on family members and carers to accomplish basic tasks. The limited treatment options have significant side effects, or require an implanted pump.
Sativex is a novel treatment developed from particular strains of cannabis that significantly improves symptoms of spasticity in responders. Because it is delivered as an oral spray, patients can adjust their dose as and when they need to. However, HCPs have been equivocal about its value, and concerned about its cost.
To drive re-appraisal of the brand among prescribers, we used the unifying idea of ‘cost’ to bring together the effect of MS spasticity on patients with its broader social impact and the financial realities, increasing their motivation to gain budget approval for Sativex.

[/box]
 
[box type=”success” ]

Mind Your Meds

The Medicine Abuse Project – Mind Your Meds

https://www.youtube.com/watch?v=BJ4kKv9-yb4

Brand: MEDICINE ABUSE PROJECT – Partnership at Drugfree.org
Agency: HILL HOLLIDAY Boston, USA
Target: Communications to Non-Healthcare Professionals
Credits:

Eric Stoltz Disorderly Conduct Director
Lance Jensen Hill Holliday Chief Creative Officer
Scott Woolwine Hill Holliday Designer/Animator
Kevin Daley Hill Holliday Group Creative Director/Art Director
Trish Fuller Whitehouse Post Editor
Tim Cawley Hill Holliday Creative Director/Copywriter
Alejandra Alarcon Disorderly Conduct Producer/Post Producer
Crash Disorderly Conduct Cinematographer
Amy Hardcastle Hill Holliday Account Team
Jenn Dodds Hill Holliday Project Manager

Campaign Description:

Teen medicine abuse is a pervasive and devastating problem, with one in four teens admitting to using a prescription drug to get high or change their mood. Most teens who report medicine abuse say they get those medications from their family or friends. The Medicine Abuse Project is a multi-year effort led by The Partnership at Drugfree.org and is designed to help combat this public health crisis deemed an “epidemic” by the Centers for Disease Control and Prevention. The Medicine Abuse Project aims to help educate parents, teens and the public about the dangers of medicine abuse and unite parents, educators, health care providers, coaches, government officials, law enforcement officers and other partners to help save lives.

[/box]
Click for the full list of Cannes Lions Health contenders and awards in Pharma category.
 

Categories
Pharma Marketing

Gartner Cool Vendors in Life Sciences 2014 – are they really cool?

Gartner Cool Vendors in Life Sciences report may be a good predictor of what will be a hot topic in pharma. But what Gartner Cool Vendors in Life Sciences 2014 really do? Is it really worth to jump the bandwagon right away?

Why Gartner Cool Vendors in Life Sciences and similar reports are important?

The mode of action is simple, consultants from Gartner and other agencies are basing on similar rankings with their sales pitches. As Richard Meyer points out, pharma marketing insiders are not the best breed.
If the sales pitch sounds good and has a supporting proof in an expensive research report, your average pharma marketer will swallow it like a hungry pelican. In the effect, any company mentioned by big consultancy has a chance to gain market and its product may be listed as a rising trend for the year to come. Regardless of the value generated for business. While you look into the Gartner Cool Vendors 2014 list, you may guess what it will be about this time.

Gartner Cool Vendors in Life Sciences 2014

Blueprint Clinical

Blueprint Clinical

Blueprint Clinical is an U.S.-based monitoring technology company founded in 2012. It’s team has a profound experience in healthcare, and especially in clinical trials. Courtney McBean, CEO of Blueprint Clinical, has over 15 years of experience in research and medical devices business.
The main product of Blueprint Clinical is web-based product called Blueprint Compass for risk-based statistical monitoring of the study performance. It provides real-time monitoring of site performance, focusing on metrics critical for the study and with possibility to assign targeted actions to relevant performance indicators.
R&D and Clinical Research is obviously the huge chunk of pharma spending, and risk-based monitoring as such is required by FDA.  Does Blueprint Clinical answers the need for that well, it is hard to assess. So far the company provides its service together with consulting service, which means that it is rather customized offer than a mature, standard service.

Liquid Grids

Liquid Grids

This one is, to be honest, a very surprising choice. Liquid Grids, a Gartner Cool Vendor in Life Sciences 2014 is PaaS solution for social media monitoring and engagement (well, they call it a “precision marketing”). Started in 2010, Liquid Grids positions itself as dedicated to health care industry. It claims that it offers “direct to patient” marketing. The problem is that from the global perspective it means a clear no go.
Pharmaceutical marketing directly to consumer is allowed only in specific markets, specifically the United States and New Zealand. What is more, from European perspective any attempt to obtain personal data and target communication to the patient without direct consent is clearly illegal.
It may be a cool vendor for Gartner, but for any pharma marketer outside of U.S. working with Liquid Grids may end with a very cold shower from your legal team (or even worse from the regulatory agency). Let us be clear, for pharma digital marketers it is extremely hard to implement even social media monitoring for product related keywords, as there is a constant awareness of drug safety obligations.

Ontoforce

Ontoforce is one of the big data vendors. Founded in 2011 company from Belgium as its main product offers a semantic search engine disQover.
Clearly, making the tons of data we have gathered in pharma searchable in a contextual way that allows discovery of unknown connections is something that may change the paradigm of research. While we are sceptical about replacing scientific method with brute force statistics on big amounts of data, there is a potential there to find new insights. On the other hand, even if Ontoforce is really Cool Vendor, the competition in this field is very strong

Pitcher

 

Pitcher is another surprising choice. eDetailing is obviously a big trend, but Pitcher is not the only one in its field. We can easily name strong contenders (or even leaders) with similar feature set. Veeva, Agnitio, Showpad and Cegedim are all offering the same service as Pitcher. We love disruptive startup companies entering digital marketing space in healthcare, but Pitcher has yet to prove its coolness.

Scigilian Software

Scigilian Software – Gartner Cool Vendors in Life Sciences 2014

Scigilian is a cloud-based software platform for managing logistics of Pharma R&D. At K-message we are specialized in digital marketing, and we cannot assess this tool capability, but the sales pitch sounds very well. Normally we could build an ERP or LIMS system for such purpose, but the solution would never be ideal. ERPs are too complex and hardly customizable, and LIMS would not cope with the complexity. The solution is to build your own software, or… ask Scigilian. Being outside of the lab, we really like the idea.
As you may see not all of the Gartner Cool Vendors in Life Sciences 2014 are cool enough to make us excited. The trends are clear, however. In pharma marketing the focus is on e-detailing, CLM and Social Media Management. In R&D hot topics are big data, clinical research support and logistics for labs.
Be prepared, consultants are coming!
 
 
 
 

Categories
Pharma Marketing

Pharma digital marketing in the U.S. Spending more and wrong.

The US Healthcare and Pharmaceutical Industry 2014: Digital Ad Spending Forecast and Trends, a new report from eMarketer shows that Pharma Marketing spending on digital remains on steady 3.0% of the total digital ad spending level. Unfortunately half of it is spent wrong.
This has been a common joke of marketers and advertisers for a long time: If I only knew which half I spend on wrong tactics I would make myself and my company rich. However, jokes aside, at K-message we can clearly see which quarter of this budget is going wrong way. We talk serious money here, healthcare and pharma ad spending is now at USD 1.41 bn level, and by 2017 we will pass the threshold of two billions.

US Healthcare and Pharma Industry Digital Ad Spending 2012-2018. Source: eMarketer.com

eMarketer takes into account all healthcare and pharmaceutical digital marketing spending in the United States. It includes prescribed (Rx) and over the counter (OTC) products, specific products and services addressed to healthcare professionals, as well as direct to consumer advertising of products, services, hospitals, health insurers etc.
More than half of this budget (56%) goes for direct response advertisement. The remainder of 44% is spent on branding campaigns. This is an artificial segmentations, as the objective of campaign usually is not so clear in the American, DTC driven market. Every branding effort may bring direct response.
What is more striking in eMarketer’s report is the share of spending on healthcare and pharma digital marketing by channel. It seems that mobile is still an ugly duckling for pharma marketers, who dedicate only 26.5% of their budget to mobile formats.
It is incredible if you look at this from the perspective. The same crowd that claims “we want more direct response and we spend more than half of our budget for it” in the same time neglects the channel that is the best to accomplish this objective.
Healthcare and pharma marketing is the single industry that spends on mobile the smallest chunk of its budget. Even PC makers spend 33% of their budget on mobile, but we in Pharma remain connected to the desktop. If we go mobile, pharma marketing focus mostly on mobile search advertisement.
US Digital Ad Spending by Industry and Channel 2014, Source: eMarketer.com

We can try to persuade ourselves, that there is some logical reasoning behind this inefficient budget allocation. However, at K-message we tend to believe that the only reason to avoid mobile advertising in pharma is simply change-aversion. Mobile advertisement is well regulated, rules are clear, and results are easily measurable. It allows better interaction than PC in many dimensions: it can be geo-located, instant, personalized. The only disadvantage over display ad on PC screen? It requires additional work.
Digital marketing is not a rocket science that Pharma R&D are performing. You can start simply with text messaging in your next multichannel campaign. Make sure that your next edetailing is part of the CLM. Give your audience some thrill with elements of gaming. Do not fly everyone to the remote conference site, use virtual one instead. This is pharma digital marketing, not putting banners every here and there.
We really hope that pharma marketers will surprise eMarketer by proving they know how to use digital marketing tactics efficiently. Fingers crossed!

 

Categories
Pharma Marketing

Text messaging in multichannel pharma marketing

Multi-channel marketing strategies usually include old tactics such as telemarketing, direct mailing and printed detail aids to accompany more fancy mobile applications, eDetailing on tablets and over the Web. Good old SMS text messaging is forgotten in the era of smartphones. Is it really so smart?

SMS in pharma marketing

Text messaging is a tactic that pharma marketers used in the past. There were successful pharma marketing campaigns with text messaging at the core of the execution.
One such example is Pfizer’s recruitment for a study that targeted teenage smokers with a radio campaign. The call to action instead of traditional “call us now” was replaced by “text us now” which allowed young audience to discreetly make a contact with researchers, even if they listened to the spot in their (unaware of teen’s deadly habit) parents’ car.
https://3.122.255.92/wp-content/uploads/2014/05/PfizerSmokingCampaignAudio.mp3?_=1
Novartis with its SMS for Life campaign allows better access to malaria treatment in Africa. A successful pilot in Tanzania that has been running since 2009, has encouraged the company to roll it out in other markets, including Kenya, Ghana and Cameroon. So far the results were very impressive, allowing company to reduce stock-outs of the antimalarial ACTs from 26% to just 1% of the facilities.
GSK is using text messaging to increase childhood vaccination rates in Mozambique and to fight counterfeit products in Tanzania. Merck is running a diabetes sms campaign in Kenya and Uganda…
But wait a moment, it is all just marginal actions, and never the core of the brand strategy in the product lifecycle. It seems that text messaging is no longer considered as a part of still trendy mobile marketing. Ask your average pharma marketing expert for mobile tactics, and you will get a standard list:
– build a mobile app
– build a mobile or responsive website
– make your e-mails mobile ready
This is all fine, but:
– a mobile app is usually a costly mistake that with limited reach and extremely short lifespan
Only 30% of apps is downloaded. Of those, only 30% is ever opened. For free apps, only 5% are still being used after one month. Astonishing 80% of mobile apps have less than 1000 downloads.
Yes, you can be lucky and make an app that is actually useful and used, as Merck was with its Clarityn’s Pollen Forecast app. But if you are in the Rx world, there is a very slight chance that a mobile app will work for you.
– a mobile or responsive website is good to have, but to convey a scientific message you need a big screen anyway. Check your current web entities for stats of mobile usage and you will be surprised how rarely HCPs are visiting it with the mobile device that is not a tablet. And for tablets, a standard website is perfectly fine.
– the e-mails are often read on mobile, that is true. Therefore, it is worth an effort to make your e-mails mobile friendly, but never stop here. If your e-mail reached a user on the mobile, the landing page should be optimized for mobile as well. Do not expect anyone to read a scientific paper on an iPhone or, even worse, Blackberry. Instead make the user journey mobile end-to-end – let them order delivery of the paper with one tap, rather than providing a download button as you would do for PC or Mac users. Limit length of the survey, make sure the landing page is light on text, etc. etc.
What your consultant probably forgot to add, a text message is much more friendly for phone users than e-mail. It can be even richer in content, especially if you decide to embed in your campaign OTT messages.
[box type=”note” ]
Text message marketing vocabulary
Short Message Service (SMS) – the oldest standard for text messaging. It allows sending 160 characters, plain text. It is extremely cheap and can be very narrowly targeted. It can reach every phone, which gives you maximum potential reach. Arriving SMS is accompanied with buzz sound set by the user, thus it is important to set silent hours for SMS campaigns.
Multimedia Messaging Service (MMS) – a standard to send messages with multimedia content to and from mobile phones. MMS can convey messages much longer than SMS, up to thousands characters or up to 1MB content. Unfortunately, its implementation differs from operator to operator and from device to device. Quality of the video and its length is also restricted, so limit yourself to 30 seconds, or use OTT instead.
Push notification – a service that allows an app installed on the device alert user with a message.If a push notification is received, an app will display it with its icon on the status bar of the device. It is useful for e-commerce applications (ie. while searching for an item, you may receive a push notification with a special time-limited offer from the merchant nearby). Unfortunately, the reach is limited to smartphones. On the other hand, users are keen on accepting Push while installing an app easier than to opt-in for SMS campaigns. Push is also cheaper than SMS.
Cross-channel messaging – messaging service can be used to seamlessly put content on other channels (ie. it is possible to receive and post Facebook comments via text messages, or use MMS to upload images on Flickr).
Over-The-Top messaging (OTT) – messaging with multimedia content that is enabled by mobile applications not associated with mobile operators (ie. Apple iMessage, WhatsUp, Blackberry Messenger). Messages are downloaded via data connection. If WiFi is used to send/receive OTT messages, it allows geolocation of the device. The best practice is to combine SMS/MMS with Push and OTT services.
Instant Messaging (IM) – real time text based communication over the Internet. From a mobile device it is non-discernible from OTT, and in some applications also merged with SMS/MMS service in one application view.
Short Code – a short, 5-6 digits, number for standard and premium rate use on assigned territories. Used for mass marketing campaigns. You can use a shared short code from your vendor to launch your campaign faster, but it will limit available keywords (each can be used only once per code). The best practice is to register single short code for your brand, especially in the long term campaigns.
Long Code – 10 digits phone numbers, as used by standard subscribers in person to person communication. They may be used for campaigns that happen across different territories, but the limitation is the amount of messages that can be processed via long code at the time.
[/box]

Advantages of SMS marketing for pharma and mobile health

 
Forgotten by external consultants in the age of pharma cross-channel marketing, mobile messaging is still alive and growing. Actually, it is the most-used non-voice channel in the world, with 14.7 trillion messages sent worldwide in 2012. With the rise of OTT and IM applications the growth of this way of communication may be even faster than expected, going well beyond an estimated 28.2 trillion threshold by 2017.
Everyone gets now text messages from banks after transactions, from airlines when the flight is ready to board, from retailers who offer us their special deals. Pharma marketers could learn from their clients how to use text messaging.
Healthcare providers are sending messages to:
– manage appointments,
– provide information,
– inform on the prescriptions
– remind patients that there is some FSA money left to be spent before the end of the year.
[box type=”info” ]
For non-US readers:
FSA stands for Flexible Spending Account and allows to pay for some medical and dental procedures or products and deduct it from the tax
[/box]
Pharmacies are sending out pick-up notices, links to package inserts content, and allow text-to-refill service to their customers.
[box type =”info”]

SMS and mobile messaging advantages for pharma marketing:

[checklist]

  • Improved relevance: Message can be easily tailored for the specific recipient, embedding itself into the CLM concept with tracking capabilities.
  • Cost efficiency: Efficiency much better than e-mail notification in terms of Open Rate (~90%). Response rate is also very high ranging from 5 to 25%, around eight times better than for e-mail.
  • Always within context: Text messages are opened at the time of receipt. You can make sure that the message content is aligned to the schedule (or even location with Push and OTT) of your recipient.
  • Providing value through the whole process of customer relationship management, from the initial opt-in confirmation at an appointment, through reminders to thank you messages. Always interactive and fully tracked!
  • Compliant: SMS/Texting follows similar pharma/healthcare industry regulations as other communications channels.

[/checklist]

Use cases for text messaging in pharma marketing and medical affairs:

[checklist]

  • Patient recruitment for clinical trials
  • Patient adherence (in clinical trials and after marketing authorization during therapy)
  • HCP and Sales Representative relationship: appointments, reminders, additional information in two-way communication

[/checklist]
[/box]

How to make a text messaging campaign that converts?

 
If you reached to this point, you are probably convinced, that text messaging is the tactic to include in your strategy. That is fine, but to make sure you are successful, we have prepared some tips and tricks, that will make your campaign better. We are all about digital marketing, so we assume you know the basics – your KPIs are already defined, and you will measure your conversion rates. So how to make sure your text message will convert?
Some of the tips are no brainers, but differ a bit in messaging campaigns from an e-mail world.
[box type=”info” ]

Tips for converting text messaging campaign

[checklist]

  • Carefully consider timing of the campaign. With an e-mail, you targeted specific days of the week. With mobile campaigns, you need to be perfectly clear about an hour (and a time zone!) when the message buzzes in your audience pockets.
  • Targeting your audience is similar to what you do in other digital channels. However, your text message will probably come from the same code through the campaign, and your audience may respond. To ensure success, first shape your communication to the audience group (ie. cardiologists), then make a tree of possible reactions and answers to them.
  • It is somewhat similar to what you would do providing a script for telemarketers. You need to think about the message as a part of longer conversation. Never repeat the same message, always refer to the previous state, and make the user journey interesting with different call-to-action.
  • Whenever you can, do A/B testing of your messages. We are aware you need to submit them to the regulatory, thus submit different versions of the message, just in case the original one is not working as well as supposed.
  • Call to action is really important, especially if you have 160 characters, and you need to make sure that there is a Fair Balance in your message. Therefore, try to embed your messaging into other elements of the campaign. The most important will always be the landing page, but text messaging allows more response types than other channels.

[/checklist]
[/box]
After receiving and viewing your message, recipient can:
[checklist]

  • call back (make sure there is a call center ready)
  • schedule an appointment with rep
  • start remote detailing
  • order samples or research paper delivery
  • watch video, document or website content
  • download an app or bookmark page
  • share some content via social media or e-mail
  • answer a short survey
  • enroll to the program
  • opt-out from the communication (you have to always provide this possibility!)
  • probably you can imagine some other responses as well

[/checklist]
As you can see there is a lot that you can do with simple message, and the more options you have in your campaign, the better results. You just need to test and fine-tune your campaign to select what works the best to deliver your key message and build valuable conversation with your audience.

Regulatory constraints for an SMS marketing in Pharma

As with every pharma marketing tactic, you must be aware of certain regulatory constraints while planning your text messaging campaign. The most important document to follow is CTIA Compliance Assurance Solution Mobile Commerce Compliance Handbook.
For U.S. run campaigns, you also need to be compliant with TCPA, HIPAA and (if you address children) COPPA regulations.

The key considerations from a regulatory compliance perspective for use of text messaging in pharma marketing:

[checklist]

  • You have a permission from the consumer to send messaging from your company (Prior Express Written Consent)
  • The short code used is the same for which consumer opted-in
  • Your campaign has been approved by carriers
  • All medical information is governed by HIPAA in terms of privacy protection
  • Consumer has always an opportunity to opt-out from all communications and is always informed about any cost that may be charged against him due to participation in your program.
  • In the U.S., according to 21 CFR 314.81(b)(3)(i), all advertisements and promotional labeling for a particular drug product must be submitted to the FDA at the time of initial publication or dissemination.  Each submission is required to be accompanied by a completed transmittal Form FDA-2253.

[/checklist]

Rich Communication: the future of mobile marketing

Mobile messaging campaigns with SMS, MMS, Push and OTT is already very efficient channel. However, the technology is going forward, and new capabilities are being rolled out. Rich Communications Services (RCS), marketed as “joyn”,  is the platform that enables the delivery of communication experiences beyond voice and SMS, providing consumers with instant messaging or chat, live video and file sharing – across devices, on any network.


With RCS, we will be able to combine in one interaction a message, video, call, and remote detailing. Joyn does not need any additional setup from the end-user. It is provided by a carrier and ready to use within compatible devices. Supported by GSMA, the technology is already being rolled out across the globe. This new standard will be yet another reason to think “messaging” as the first option where it comes to mobile marketing.

Exit mobile version